Latest filing published 15 Oct 2026 for CRISPR Therapeutics AG.
James R. Kasinger, listed as board member, appears in our data through filings on CRISPR Therapeutics AG shares, published by SEC (Form 4). We count 60 filings; the first trade dates from 9 December 2020 and the latest from 14 October 2026.
The open-market record consists of 22 sales worth €7.3M, with no purchase. Other entries cover 9 share grants and 29 option exercises. Since January 2026: no purchases and 7 sales on the market.
Most recently, on 15 October 2026, the filings show an option exercise in CRISPR Therapeutics AG. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations